© 2020 MJH Life Sciences, Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
All News
FDA Approves Guardant360 CDx for Tumor Mutation Profiling of All Solid Cancers
August 10, 2020
The FDA has approved the Guardant360 CDx liquid biopsy for tumor mutation profiling in patients with any solid malignant neoplasm. This represents the first liquid biopsy companion that is FDA-approved for comprehensive tumor mutation profiling across all solid tumors.
Enzastaurin and a Novel Biomarker Spark Optimism for All Risk Levels of DLBCL
August 09, 2020
In an interview with Targeted Oncology, Grzegorz S. Nowakowski, MD, discussed the promise of the enzastaurin in the diffuse large B-cell lymphoma treatment landscape and the ongoing phase 3 ENGINE study.
R-CHOP Alone Should Be New Standard in Early-Stage DLBCL, Researchers Say
August 08, 2020
Four cycles of R-CHOP alone should be the new standard approach to limited-stage disease for the majority of patients with diffuse large B-cell lymphoma. That’s the conclusion of a new study that used positron emission tomography–directed treatment approaches to assess the outcomes and toxicity associated with the current standard of care.
New Analysis of Somatic Alterations Identifies Low-Risk Multiple Myeloma Subgroup
August 08, 2020
A new study has identified genomic factors that appear to correlate with a better risk profile and better progression-free survival among patients with multiple myeloma. The findings, though preliminary, could someday lead to better patient empowerment and stratification.
CS1001 Plus Chemotherapy Prolongs Progression-Free Survival in Stage IV NSCLC
August 07, 2020
The combination of CS1001 and chemotherapy led to an improvement in progression-free survival among patients with stage IV squamous and non-squamous non–small cell lung cancer, according to data from the phase 3 CS1001-302 clinical trial assessed by an Independent Data Monitoring Committee, achieving the study’s primary end point.
First-Line Pembrolizumab Demonstrates Promising Activity in Phase 2 of Cutaneous Squamous Cell Carcinoma
August 07, 2020
Frontline treatment with the immune checkpoint inhibitor pembrolizumab as monotherapy generated promising activity against cutaneous squamous cell carcinoma with durable responses and a manageable safety profile.
Trending News on Targeted Oncology, Week of August 7, 2020
August 07, 2020
Targeted Oncology reviews trending news online for the week of August 7, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.
Omburtamab BLA Submitted for FDA Approval in CNS/Leptomeningeal Metastasis From Neuroblastoma
August 06, 2020
A completed Biologics License Application was submitted to the FDA for omburtamab, an investigation monoclonal antibody, which is intended for the treatment of pediatric patients with central nervous system/leptomeningeal metastasis from neuroblastoma.
Frontline Triplet Generates High Response Rates in Treatment-Naïve CLL
August 06, 2020
The triplet combination of obinutuzumab plus ibrutinib with venetoclax demonstrated encouraging response rates in patients with treatment-naïve chronic lymphocytic leukemia.
Autologous CAR T-Cell Therapy Induces Durable Responses in Relapsed/Refractory Hodgkin Lymphoma
August 06, 2020
"These data are significant, as they demonstrate that CAR T-cell therapy may be a safe and effective treatment option for patients with Hodgkin lymphoma and potentially other lymphomas expressing the CD30 antigen."